Patent SG-11201810199W-A (SG)
Title: ANTI-IgE ANTIBODIES
Inventor: ADAMS RALPH
IPC: C07K16/42
Filed: 2017-06-08
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization MD HIM 01E111 Minn 01111111 HIM 1 1111 EH ill 1111111 International Bureau (43) International Publication Date . . .., . .. WO 2017/211928 Al (10) International Publication Number 14 December 2017 (14.12.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/28 (2006.01) C07K 16/42 (2006.01) C07K 14/735 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (21) International Application Number: PCT/EP2017/063916 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (22) International Filing Date: 08 June 2017 (08.06.2017) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1610198.2 10 June 2016 (10.06.2016) GB 1702435.7 15 February 2017 (15.02.2017) GB kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicant: UCB BIOPHARMA SPRL [BE/BE]; 60, Al- lee de la Recherche, 1070 Brussels (BE). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (72) Inventors: ADAMS, Ralph; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). CESKA, Thomas Allen; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). DAVIES, Anna Marie; MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). King's College London, Randall Division of Cell & Mol- Declarations under Rule 4.17: ecular Biophysics, MRC & Asthma UK Centre in Aller- — as to applicant's entitlement to apply for and be granted a gic Mechanisms of Asthma, New Hunt's House, Guy's Hos- patent (Rule 4.17(ii)) pital Campus London SE1 1UL (GB). HENRY, Alistair — of inventorship (Rule 4.17(iv)) James; c/o IPD, UCB Celltech, 208 Bath Road, Slough Published: Berkshire SL1 3WE (GB). LIU, Xiaofeng; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). — with international search report (Art. 21 (3)) — before the expiration of the time limit for amending the MCDONNELL, James Michael; King's College London, Randall Division of Cell & Molecular Biophysics, MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, New Hunt's House, Guy's Hospital Campus London SE1 claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) 1UL (GB). SUTTON, Brian John; King's College London, Randall Division of Cell & Molecular Biophysics, MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, New Hunt's House, Guy's Hospital Campus London SE1 1UL (GB). WESTWOOD, Marta Katarzyna; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). Agent: UCB INTELLECTUAL PROPERTY; c/o UCB (74) = Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). ,_ 1 (54) Title: ANTI-IgE ANTIBODIES (57) : The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions GO thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune 6m el responses); and, in particular, disorders caused by the interaction of IgE with the FccRI receptor. In particular, this invention relates ;L to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE - antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the --.... \" Cz2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cz2 domain of IgE) and/or the Ir- ability to disassociate IgE from the FccRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved Il © or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with N 1 the FccRI receptor). C